MiR-541-5p regulates lung fibrosis by targeting cyclic nucleotide phosphodiesterase 1A

References

• Hardie WD, Glasser SW, Hagood JS. Emerging concepts in the pathogenesis of lung fibrosis. Am J Pathol. 2009;175(1):3–16. Epub 2009/06/06.
   PubMed Web of Science ®Google Scholar
• Tomasek JJ, Gabbiani G, Hinz B, Chaponnier C, Brown RA. Myofibroblasts and mechano-regulation of connective tissue remodelling. Nat Rev Mol cell biol. 2002;3(5):349–363. Epub 2002/05/04.
   PubMed Web of Science ®Google Scholar
• Hinz B, Phan SH, Thannickal VJ, Prunotto M, Desmouliere A, Varga J, et al. Recent developments in myofibroblast biology: paradigms for connective tissue remodeling. Am J Pathol. 2012;180(4):1340–1355. Epub 2012/03/06.
   PubMed Web of Science ®Google Scholar
• Wolters PJ, Collard HR, Jones KD. Pathogenesis of idiopathic pulmonary fibrosis. Annu Rev Pathol. 2014;9:157–179.
   PubMed Web of Science ®Google Scholar
• Rafii R, Juarez MM, Albertson TE, Chan AL. A review of current and novel therapies for idiopathic pulmonary fibrosis. J Thorac Dis. 2013;5(1):48–73.
   PubMed Web of Science ®Google Scholar
• Ramirez AM, Shen Z, Ritzenthaler JD, Roman J. Myofibroblast transdifferentiation in obliterative bronchiolitis: tgf-beta signaling through smad3-dependent and -independent pathways. Am J Transplant: Off J Am Soc Transplant Am Soc Transplant Surg. 2006;6(9):2080–2088.
   Google Scholar
• Michalski J, Kanaji N, Liu X, Nogel S, Wang X, Basma H, et al. Attenuation of inhibitory prostaglandin E2 signaling in human lung fibroblasts is mediated by phosphodiesterase 4. Am J Respir Cell Mol Biol. 2012;47(6):729–737.
   PubMed Web of Science ®Google Scholar
• Selige J, Tenor H, Hatzelmann A, Dunkern T. Cytokine-dependent balance of mitogenic effects in primary human lung fibroblasts related to cyclic AMP signaling and phosphodiesterase 4 inhibition. J Cell Physiol. 2010;223(2):317–326.
   PubMed Web of Science ®Google Scholar
• Zieba BJ, Artamonov MV, Jin L, Momotani K, Ho R, Franke AS, et al. The cAMP-responsive Rap1 guanine nucleotide exchange factor, Epac, induces smooth muscle relaxation by down-regulation of RhoA activity. J Biol Chem. 2011;286(19):16681–16692.
   PubMed Web of Science ®Google Scholar
• Nagel DJ, Aizawa T, Jeon KI, Liu W, Mohan A, Wei H, et al. Role of nuclear Ca2+/calmodulin-stimulated phosphodiesterase 1A in vascular smooth muscle cell growth and survival. Circ Res. 2006;98(6):777–784. Epub 2006/03/04.
   PubMed Web of Science ®Google Scholar
• Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell. 2004;116(2):281–297. Epub 2004/01/28.
   PubMed Web of Science ®Google Scholar
• Zeng Y. Principles of micro-RNA production and maturation. Oncogene. 2006;25(46):6156–6162. Epub 2006/10/10.
   PubMed Web of Science ®Google Scholar
• Engels BM, Hutvagner G. Principles and effects of microRNA-mediated post-transcriptional gene regulation. Oncogene. 2006;25(46):6163–6169. Epub 2006/10/10.
   PubMed Web of Science ®Google Scholar
• Bushati N, Cohen SM. microRNA functions. Annu Rev Cell Dev Biol. 2007;23:175–205. Epub 2007/05/18.
   PubMed Web of Science ®Google Scholar
• Ambros V. microRNAs: tiny regulators with great potential. Cell. 2001;107(7):823–826. Epub 2002/01/10.
   PubMed Web of Science ®Google Scholar
• Croce CM. Causes and consequences of microRNA dysregulation in cancer. Nat Rev Genet. 2009;10(10):704–714. Epub 2009/09/19.
   PubMed Web of Science ®Google Scholar
• Croce CM, Calin GA. miRNAs, cancer, and stem cell division. Cell. 2005;122(1):6–7. Epub 2005/07/13.
   PubMed Web of Science ®Google Scholar
• Pandey AK, Agarwal P, Kaur K, Datta M. MicroRNAs in diabetes: tiny players in big disease. Cell Physiol Biochem: Int J Exp Cell Physiol, Biochem Pharmacology. 2009;23(4–6):221–232. Epub 2009/05/28.
   Google Scholar
• Latronico MV, Condorelli G. MicroRNAs and cardiac pathology. Nat rev Cardiol. 2009;6(6):419–429. Epub 2009/05/13.
   PubMed Web of Science ®Google Scholar
• Thum T, Catalucci D, Bauersachs J. MicroRNAs: novel regulators in cardiac development and disease. Cardiovasc Res. 2008;79(4):562–570. Epub 2008/05/31.
   PubMed Web of Science ®Google Scholar
• Mishra PK, Tyagi N, Kumar M, Tyagi SC. MicroRNAs as a therapeutic target for cardiovascular diseases. J Cell Mol Med. 2009;13(4):778–789. Epub 2009/03/27.
   PubMed Web of Science ®Google Scholar
• Thum T, Gross C, Fiedler J, Fischer T, Kissler S, Bussen M, et al. MicroRNA-21 contributes to myocardial disease by stimulating MAP kinase signalling in fibroblasts. Nature. 2008;456(7224):980–984. Epub 2008/12/02.
   PubMed Web of Science ®Google Scholar
• Liu G, Friggeri A, Yang Y, Milosevic J, Ding Q, Thannickal VJ, et al. miR-21 mediates fibrogenic activation of pulmonary fibroblasts and lung fibrosis. J Exp Med. 2010;207(8):1589–1597. Epub 2010/07/21.
   PubMed Web of Science ®Google Scholar
• Bitko V, Musiyenko A, Shulyayeva O, Barik S. Inhibition of respiratory viruses by nasally administered siRNA. Nat Med. 2005;11(1):50–55.
   PubMed Web of Science ®Google Scholar
• Zhao H, Bian H, Bu X, Zhang S, Zhang P, Yu J, et al. Targeting of discoidin domain receptor 2 (DDR2) prevents myofibroblast activation and neovessel formation during pulmonary fibrosis. Mol Ther: J Am Soc Gene Ther. 2016;24(10):1734–1744. Epub 2016/06/29.
   Google Scholar
• Lu J, Getz G, Miska EA, Alvarez-Saavedra E, Lamb J, Peck D, et al. MicroRNA expression profiles classify human cancers. Nature. 2005;435(7043):834–838. Epub 2005/06/10.
   PubMed Web of Science ®Google Scholar
• Zhang C. MicroRNomics: a newly emerging approach for disease biology. Physiol Genomics. 2008;33(2):139–147. Epub 2008/02/28.
   PubMed Web of Science ®Google Scholar
• Pandit KV, Corcoran D, Yousef H, Yarlagadda M, Tzouvelekis A, Gibson KF, et al. Inhibition and role of let-7d in idiopathic pulmonary fibrosis. Am J Respir. Crit Care Med. 2010;182(2):220–229. Epub 2010/04/17.
   PubMed Web of Science ®Google Scholar
• Xie T, Liang J, Guo R, Liu N, Noble PW, Jiang D. Comprehensive microRNA analysis in bleomycin-induced pulmonary fibrosis identifies multiple sites of molecular regulation. Physiol Genomics. 2011;43(9):479–487. Epub 2011/01/27.
   PubMed Web of Science ®Google Scholar
• Ogawa T, Enomoto M, Fujii H, Sekiya Y, Yoshizato K, Ikeda K, et al. MicroRNA-221/222 upregulation indicates the activation of stellate cells and the progression of liver fibrosis. Gut. 2012;61(11):1600–1609. Epub 2012/01/24.
   PubMed Web of Science ®Google Scholar
• Liu F, Li N, Long B, Fan YY, Liu CY, Zhou QY, et al. Cardiac hypertrophy is negatively regulated by miR-541. Cell Death Disease. 2014;5:e1171. Epub 2014/04/12.
   PubMed Web of Science ®Google Scholar
• Yang F, Xu Z, Duan S, Luo M. MicroRNA-541 promotes the proliferation of vascular smooth muscle cells by targeting IRF7. Am J Translational Res. 2016;8(2):506–515. Epub 2016/05/10.
   PubMed Web of Science ®Google Scholar
• Conti M, Beavo J. Biochemistry and physiology of cyclic nucleotide phosphodiesterases: essential components in cyclic nucleotide signaling. Annu Rev Biochem. 2007;76:481–511. Epub 2007/03/23.
   PubMed Web of Science ®Google Scholar
• Lugnier C. Cyclic nucleotide phosphodiesterase (PDE) superfamily: a new target for the development of specific therapeutic agents. Pharmacol Ther. 2006;109(3):366–398. Epub 2005/08/17.
   PubMed Web of Science ®Google Scholar
• Bornfeldt KE. Nuclear signaling in smooth muscle cells: cyclic nucleotide phosphodiesterase 1A moves in. Circ Res. 2006;98(6):720–722. Epub 2006/04/01.
   PubMed Web of Science ®Google Scholar
• Xie Y, Jiang H, Zhang Q, Mehrotra S, Abel PW, Toews ML, et al. Upregulation of RGS2: a new mechanism for pirfenidone amelioration of pulmonary fibrosis. Respir Res. 2016;17(1):103. Epub 2016/08/24.
   PubMed Web of Science ®Google Scholar
• Abbott-Banner KH, Page CP. Dual PDE3/4 and PDE4 inhibitors: novel treatments for COPD and other inflammatory airway diseases. Basic Clin Pharmacology Toxicol. 2014;114(5):365–376. Epub 2014/02/13.
   PubMed Web of Science ®Google Scholar